| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03773302 2018-004004-19 Details | 2023-04-03 Interventional | 3 | 48 | Gemcitabine Infigratinib Cholangiocarcin… Advanced Cholan… FGFR2 Gene Muta… | The sponsor has decided to close the study due to the discontinuation of infigratinib
development in oncology within the sponsor's territory. The discontinuation of the study was
not due to safety issues. - | |||
| NCT03254927 Details | 2023-04-03 Interventional | 2 | 30 | Cetuximab Carcinoma Carcinoma, Squa… Squamous Cell C… Advanced Head a… | Sponsor decision based on emerging risk-benefit profile Study was terminated early due to unfavorable risk/benefit profile. | |||
| NCT04513314 Details | 2023-03-31 Interventional | 4 | 0 | Quetiapine Fuma… Valproic Acid COVID-19 Delirium Pneumonia Pneumonia, Vira… Covid19 Hyperactive Del… | coronavirus omicron variant infection typically not associated with delirium and agitation
severely hampered recruitment. - | |||
| NCT02728037 Details | 2023-03-31 Interventional | 3 | 38 | Lidocaine Magnesium Sulfa… Pelvic Pain | Low Enrollment, Adoption of investigational treatment into standard practice at our center. - | |||
| NCT00251433 2005-000846-35 Details | 2023-03-31 Interventional | 1 | [1 Refs] | 53 | Docetaxel Lapatinib Trastuzumab Breast Neoplasm… Neoplasms, Brea… | EGF100161 (NCT00251433) was terminated in Phase I (Phase II expansion portion of the study was
never initiated) by sponsor decision. - | ||
| NCT03406715 Details | 2023-03-30 Interventional | 2 | 14 | Ipilimumab Nivolumab Lung Neoplasms Small Cell Lung… Lung Cancer Relapsed Small … Small Cell Lung… | Sponsor closed study - | |||
| NCT03019588 Details | 2023-03-30 Interventional | 3 | 94 | Paclitaxel Pembrolizumab Adenocarcinoma Esophageal Neop… Stomach Neoplas… Gastric Neoplas… Gastroesophagea… | Business Reasons - | |||
| NCT01709136 Details | 2023-03-30 Interventional | 2/3 | 3 | MTOR Inhibitors Sirolimus Tacrolimus Temsirolimus Hypertension | Sirolimus usage discontinued since black box warning Complete follow-up failed, due to early study termination as a result of FDA black box warning (6/11/2009) about Sirolimus in liver transplant recipients (risk of thrombosis and death). | |||
| NCT00572156 2019-000843-29 Details | 2023-03-30 Interventional | 2 | 106 | Mecasermin Dwarfism Insulin-like Gr… | The study was prematurely terminated due to strategic reasons. The study was prematurely terminated once the last subject had completed three years of treatment (compared to the six years planned in protocol Amendment) for strategic reasons. | |||
| NCT03426254 Details | 2023-03-29 Interventional | 1 | 0 | Talazoparib Breast Neoplasm… Advanced or Rec… Breast Neoplasm | the company is liquidated - | |||
| NCT03108690 Details | 2023-03-29 Interventional | 4 | 0 | Ampicillin Anti-Bacterial … Antibiotics, An… Beta Lactam Ant… Cefuroxime Dicloxacillin Lactams Meropenem Penicillin G Piperacillin Piperacillin, T… Tazobactam beta-Lactams Bacteremia | Logistics - | |||
| NCT02825576 Details | 2023-03-29 Interventional | 4 | [1 Refs] | 30 | Glycopyrrolate Neostigmine Pulmonary Compl… | Lack of Study Personnel - | ||
| NCT05321524 Details | 2023-03-28 Interventional | 2 | 7 | Chenodeoxycholi… Biliary Atresia | After extensive efforts to improve recruitment, it is deemed not feasible to enroll the
requisite number of subjects to generate data needed to meet the study objectives. EMA
Paediatric Committee agreed with the Sponsor to terminate this study. - | |||
| NCT05077085 Details | 2023-03-28 Interventional | 4 | 0 | Vancomycin Clostridium Inf… Enterocolitis Enterocolitis, … Infections Clostridioides … | Withdrawn - | |||
| NCT04836533 Details | 2023-03-28 Interventional | 1 | 0 | Antidepressive … Depression Depressive Diso… Depression in O… | Conflicts at the study site prevented the study from being carried out - | |||
| NCT04374253 2020-000766-42 Details | 2023-03-28 Interventional | 3 | 1379 | Antibodies, Mon… Alzheimer Disea… | Decision to terminate development of Gantenerumab for treatment of prodromal/mild/early-stage
Alzheimer's disease following results of a pre-planned analysis of the safety and efficacy of
Gant in Graduate I&II (WN29922/WN39658). - | |||
| NCT03433755 Details | 2023-03-27 Interventional | 3 | 259 | Evolocumab Dyslipidemias Hypercholestero… Mixed Dyslipide… Primary Hyperch… | Prematurely Discontinued Amgen decision - | |||
| NCT05079360 Details | 2023-03-24 Interventional | 2 | 0 | Estrogen Recept… Estrogens Everolimus Exemestane Selective Estro… Breast Neoplasm… Metastatic Brea… | Decided to halt and will potentially reopen in the future. - | |||
| NCT05012787 Details | 2023-03-24 Interventional | 3 | 1 | 1018 oligonucle… Vaccines COVID-19 | The study was early terminated considering the inability to enroll the required study
population. - | |||
| NCT04809116 Details | 2023-03-24 Interventional | 4 | 0 | Pimavanserin Sleep Initiatio… Stress Disorder… Stress Disorder… Insomnia Chroni… Posttraumatic S… | Received alternative sources of funding. - |